Locally Advanced Non-Small Cell Lung Cancer (DBCOND0039376)

Identifiers

Synonyms

Locally Advanced Non Small Cell Lung Cancer (NSCLC) / Locally Advanced Non Small Cell Lung Cancer (NSCLC)* / Locally Advanced NSCLC / Locally advanced Non small cell lung cancer / Locally Advanced Lung Non-Small Cell Carcinoma / Lung Cancer Non-Small Cell Stage III / Nonsmall Cell Lung Cancer Stage III / Non Small Cell Lung Cancer Stage III / Non-Small Cell Lung Cancer (Stage III) / Stage III Non-small-Cell Lung Cancer / Non Small Cell Lung Cancer (Stage III) / Stage III Non-Small Cell Lung Cancer / Non-small Cell Lung Cancer, Stage III / NSCLC, Stage III / Stage III NSCLC / Non-small Cell Lung Cancer Stage III / Stage 3 Non-small cell lung cancer / Locally advanced Non-Small Cell Lung Cancer

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Adagrasib	A KRAS inhibitor indicated for the treatment of locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy.	GTPase KRastarget Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Cytochrome P450 1A2enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2D6enzyme ATP-dependent translocase ABCB1transporter
Amivantamab	An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.	Epidermal growth factor receptortarget Hepatocyte growth factor receptortarget Low affinity immunoglobulin gamma Fc region receptor III-Atarget
Cemiplimab	A programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.	Programmed cell death protein 1target
Chymotrypsin	A digestive enzyme supplement used as supportive therapy to manage the side effects associated with conventional chemotherapy, radiotherapy, and hormone therapy.	No drug targets
Lazertinib	A tyrosine kinase inhibitor used in combiantion with amivantamab to treat non-small cell lung cancer with EGFR mutations.	Cytochrome P450 3A4enzyme Broad substrate specificity ATP-binding cassette transporter ABCG2transporter UDP-glucuronosyltransferase 1A1enzyme Glutathione S-transferase Mu 1enzyme Solute carrier family 22 member 1transporter Epidermal growth factor receptortarget
Mobocertinib	An oral kinase inhibitor targeted against EGFR and used in the treatment of NSCLC with EGFR exon 20 insertion mutations.	Epidermal growth factor receptortarget Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Osimertinib	A tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung carcinoma.	Epidermal growth factor receptortarget ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 3A4enzyme Cytochrome P450 1A2enzyme
Paclitaxel	A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer.	Apoptosis regulator Bcl-2target Tubulin beta-1 chaintarget Cytochrome P450 2C8enzyme Cytochrome P450 3A4enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Bile salt export pumptransporter ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 10transporter Aromataseenzyme Cytochrome P450 1B1enzyme Solute carrier organic anion transporter family member 1B3transporter Nuclear receptor subfamily 1 group I member 2target Microtubule-associated protein 4target Microtubule-associated protein 2target Microtubule-associated protein tautarget ATP-binding cassette sub-family C member 2transporter
Sotorasib	An experimental KRAS inhibitor being investigated for the treatment of KRAS G12C mutant non small cell lung cancer, colorectal cancer, and appendix cancer.	GTPase KRastarget Cytochrome P450 3A Subfamilyenzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2B6enzyme Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter
Vinorelbine	A vinca alkaloid used in the treatment of metastatic non-small cell lung carcinoma (NSLC) and in conjunction with other drugs in locally advanced NSCLC.	Tubulin beta chaintarget Cytochrome P450 3A4enzyme Cytochrome P450 2D6enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06066138	A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	Atezolizumab	treatment	1	not_yet_recruiting
NCT03741647	Sleep Apnea and Lung Cancer	No drug interventions	Not Available	Not Available	unknown_status
NCT05111197	Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy	No drug interventions	treatment	3	recruiting
NCT03886441	Prevention of Locally Advanced NSCLC Radiotherapy Pneumonia by Inhaling Beclomethasone Propionate	Beclomethasone dipropionate Propionate ion	prevention	2	unknown_status
NCT03801902	Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial	Durvalumab Monalizumab Oleclumab	treatment	1	suspended
NCT04013542	Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT05624996	Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer	Beta-D-Glucose Carboplatin Chloride ion Cisplatin Durvalumab Etoposide Paclitaxel Pemetrexed Platinum	treatment	3	recruiting
NCT04940299	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma	Ipilimumab Nivolumab Tocilizumab	treatment	2	active_not_recruiting
NCT04751747	Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer	No drug interventions	supportive_care	Not Available	recruiting
NCT04227028	Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC	Bevacizumab Brigatinib	treatment	1	active_not_recruiting
NCT05166616	Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer	Minnelide Osimertinib Triptolide	treatment	1	recruiting
NCT04372927	ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy	Beta-D-Glucose Chloride ion Cisplatin Durvalumab Etoposide Pemetrexed Platinum	treatment	2	terminated
NCT05136846	Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer	Carboplatin Durvalumab Paclitaxel Papaverine Pemetrexed	treatment	1	recruiting
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT06361784	Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)	No drug interventions	Not Available	Not Available	recruiting
NCT05010109	Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation	No drug interventions	diagnostic	1	recruiting
NCT02595866	Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	Pembrolizumab	treatment	1	completed
NCT05291780	Stereotactic Ablative Radiotherapy in Locally Advanced Non Small Cell Lung Cancer	No drug interventions	treatment	Not Available	completed
NCT01118676	Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer	Cilengitide	treatment	1	completed
NCT04606303	A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.	Platinum Toripalimab	treatment	2	enrolling_by_invitation
NCT00614484	Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer	Carboplatin Paclitaxel	treatment	1 / 2	terminated
NCT04648033	Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC	Atovaquone Cisplatin Vinorelbine	treatment	1	completed
NCT00886405	Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer	Nitroglycerin	treatment	2	unknown_status
NCT00702975	Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy	Bevacizumab Carboplatin Erlotinib Paclitaxel	treatment	2	completed
NCT05481775	Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer	Anlotinib	treatment	2	withdrawn
NCT04153734	Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC	Carboplatin Paclitaxel Pembrolizumab Pemetrexed Platinum	treatment	2	unknown_status
NCT04749394	A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy	Camrelizumab Rivoceranib	treatment	2	recruiting
NCT01059552	Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	Vorinostat	treatment	1	completed
NCT05620199	Upfront Resection of Locally Advanced NSCLC Followed by Chemoradiotherapy	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT06287320	The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer	No drug interventions	Not Available	Not Available	recruiting
NCT01537991	ISoToxic Accelerated RadioTherapy in Locally Advanced Non-small Cell Lung Cancer: The Phase I/II I-START Trial	No drug interventions	treatment	Not Available	completed
NCT05339568	Patient's Whole Process Follow-up Management(HOPE-1)	No drug interventions	Not Available	Not Available	recruiting
NCT03371550	A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy	Cisplatin Docetaxel	treatment	2	completed